Transcriptomics, metabolomics, lipidomics, metabolic flux and mGWAS analyses of sphingolipid pathway highlights novel drugs for Alzheimer’s disease

MLA

Priyanka Baloni, et al. “Transcriptomics, Metabolomics, Lipidomics, Metabolic Flux and MGWAS Analyses of Sphingolipid Pathway Highlights Novel Drugs for Alzheimer’s Disease.” Alzheimer’s & Dementia, vol. 17, Dec. 2021. EBSCOhost, https://doi.org/10.1002/alz.056152.

APA

Priyanka Baloni, Matthias Arnold, Herman Moreno, Kwangsik Nho, Gabi Kastenmüller, Karsten Suhre, Luna Buitrago, Gregory Louie, Alexandra Kueider‐Paisley, Andrew J. Saykin, Kim Ekroos, Peter J. Meikle, Kevin Huynh, Cory C. Funk, Leroy Hood, Nathan D. Price, Rebecca Baillie, Xianlin Han, & Rima F. Kaddurah‐Daouk. (2021). Transcriptomics, metabolomics, lipidomics, metabolic flux and mGWAS analyses of sphingolipid pathway highlights novel drugs for Alzheimer’s disease. Alzheimer’s & Dementia, 17. https://doi.org/10.1002/alz.056152

Chicago

Priyanka Baloni, Matthias Arnold, Herman Moreno, Kwangsik Nho, Gabi Kastenmüller, Karsten Suhre, Luna Buitrago, et al. 2021. “Transcriptomics, Metabolomics, Lipidomics, Metabolic Flux and MGWAS Analyses of Sphingolipid Pathway Highlights Novel Drugs for Alzheimer’s Disease.” Alzheimer’s & Dementia 17 (December). doi:10.1002/alz.056152.